we were properly informed that the research organisation has...

we were properly informed that the research organisation has been engaged to coordinate sites, enrollment etc. so this isnt a surprise. assuming it is ours. i expect they should get up and running fairly quickly because many of the sites would be familiar with the procedures,.e.g. thawing , injecting etc. from last trial. and the specialists have been saying they need a treatment., so should already have plenty of patients ready and waiting. its a 12 month follow up primary endpoint. and has rmat designation..
so after first patient dosed, according to above it might not show for up to 3 weeks on clinical trials. it will be under the name Rexlemestrocel, revascor is the name used for heart failure although same product.
i hope they give us a first patient dosed announcement, will lift our spirits a bit.
i can't remember a time when the forum has been this quiet. if you are a contrarian investor, maybe that's a sign.
i still suspect partering on this might be reserved as the last option until after our position is known on gvhd and we find out how attractive the heart failure program looks for partnering after feedback.